Biovail Corporation, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products used in the treatment of specialty central nervous system disorders. Its product portfolio includes Wellbutrin XL for the treatment of depression in adults; Xenazine for the treatment of chorea associated with Huntington's disease; Aplenzin for the treatment of major depressive disorder; Zovirax Ointment for the management of initial genital herpes; Zovirax Cream for the treatment of herpes labialis; Ultram ER for the management of chronic pain in adults; and Cardizem LA that provides blood pressure control. The company also provides Tiazac/Tiazac XC for the treatment of hypertension and angina; Wellbutrin SR for the treatment of depression; Glumetza for the control of hyperglycemia in adult patients with type 2 diabetes; Ralivia for the management of pain of moderate severity; Nitoman for the treatment of hyperkinetic movement disorders; Cardizem CD medications in the calcium channel blocker category of cardiovascular drugs; and Zyban for smoking cessation treatment. In addition, it distributes various other pharmaceutical products, including Ativan for the management of anxiety disorders; Vasotec and Vaseretic for the treatment of hypertension, symptomatic congestive heart failure, and asymptomatic left ventricular dysfunction; and Isordil to treat prophylaxis of ischemic heart pain associated with coronary insufficiency. The company’s generic products consist of bioequivalent formulations of Cardizem CD, Adalat CC, Procardia XL, Tiazac, Voltaren XR, and Trental. In addition, it offers research, development, and clinical contract research services to third parties. The company distributes its products primarily through third party commercialization relationships in the United States and Canada. Biovail Corporation was founded in 1983 and is headquartered in Mississauga, Canada.

Elan Corporation, plc operates as a neuroscience-based biotechnology company primarily in Ireland and the United States. It operates in two segments, BioNeurology and Elan Drug Technologies (EDT). The BioNeurology segment engages in the research, development, and commercial activities primarily in the areas of Alzheimer’s disease, Parkinson’s disease, multiple sclerosis (MS), Crohn’s disease, and severe chronic pain. Its offers Tysabri to treat relapsing forms of MS; Prialt, a non-opioid and intrathecal analgesic for the treatment of severe chronic pain, principally neuropathic pain; Azactam, a monobactam to treat pneumonia, post-surgical infections, and septicemia; and Maxipime, an injectable cephalosporin antibiotic used to treat patients with serious and/or life-threatening infections. This segment in collaboration with Biogen Idec, Inc., develops and markets Tysabri for the treatment for Crohn’s disease. It also develops beta amyloid immunotherapies for the treatment of Alzheimer’s disease through collaboration with Wyeth. In addition, this segment develops ELND005, a novel therapeutic agent, which is in Phase II clinical study to treat Alzheimer’s disease; ELND006, a small molecule gamma secretase inhibitor is in Phase I clinical studies for the treatment of Alzheimer’s disease; and Beta secretase, a precursor to plaque development in the brain. Further, BioNeurology segment has collaboration agreement with PharmatrophiX to develop small molecule ligands for growth factor receptors relevant to neurological disorders. The EDT segment offers pharmaceutical products using its proprietary drug technologies. It also provides formulation development services and contract manufacturing services that include analytical development, clinical trial manufacturing, scale-up, product registration support, and supply chain management. Elan Corporation sells its products primarily to drug wholesalers. The company was founded in 1969 and is headquartered in Dublin, Ireland.